& Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan from two studies that recruited patients with lung and breast cancer. The company released first-time data from the open-label Phase II trial (NCT05351788) in patients with advanced non-small cell lung cancer (NSCLC) along with additional data from the Phase III study (NCT05347134) with the ADC in patients with advanced or metastatic triple-negative breast cancer. The gold standard of business intelligence.
The results will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from 31 May to 4 June. Sacituzumab tirumotecan is a trophoblast cell-surface antigen 2 (TROP2)-targeting antibody linked to a belotecan-derivative topoisomerase I inhibitor payload. It has the same antibody as the ’ (sacituzumab govitecan), but has a different payload and linker.
MSD from China-based Sichuan Kelun-Biotech (Kelun) in 2022. The Phase II trial evaluated sacituzumab tirumotecan in combination with Kelun’s programmed cell death-ligand 1 (PD-L1) targeting monoclonal antibody, KL-A167, in treatment naïve NSCLC patients. The patients were non-randomised to receive 5 mg/kg of sacituzumab tirumotecan every three weeks (Q3W) in addition to either 1,200 mg of KL-A167 Q3W (cohort 1A) or 900 mg of KL-A167 once every two weeks (cohort 1B).
As of 2 Jan 2024, the 40 participants in cohort 1A, who had a longer median follow up of 14.
